Fresh Tracks Therapeutics (NASDAQ:FRTX) PT Lowered to $4.00

Fresh Tracks Therapeutics (NASDAQ:FRTXGet Rating) had its price target decreased by Oppenheimer to $4.00 in a report released on Wednesday, Stock Target Advisor reports. Oppenheimer’s price target would indicate a potential upside of 87.79% from the stock’s previous close. Oppenheimer also issued estimates for Fresh Tracks Therapeutics’ Q4 2022 earnings at ($1.80) EPS, FY2022 earnings at ($0.36) EPS, Q1 2023 earnings at ($0.32) EPS, Q2 2023 earnings at ($0.30) EPS, Q3 2023 earnings at ($0.30) EPS, Q4 2023 earnings at ($0.30) EPS, FY2023 earnings at ($1.21) EPS, FY2024 earnings at ($1.40) EPS, FY2025 earnings at ($0.70) EPS and FY2026 earnings at ($0.74) EPS.

Fresh Tracks Therapeutics Stock Down 4.5 %

Shares of FRTX opened at $2.13 on Wednesday. Fresh Tracks Therapeutics has a 12-month low of $1.67 and a 12-month high of $18.94. The company’s fifty day moving average is $1.89.

About Fresh Tracks Therapeutics

(Get Rating)

Fresh Tracks Therapeutics, Inc, a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors.

Recommended Stories

Stock Target Advisor logo

Receive News & Ratings for Fresh Tracks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresh Tracks Therapeutics and related companies with's FREE daily email newsletter.